 During this observational study patients will be treated under standard care with either statin therapy andor co-administered with ezetimibe 10 mg day. This is an open label observational study, therefore patients and physicians will be aware of treatment allocation and the treatment chosen will be that in the best interests of the patient and according to the physicians preference. Treatment will begin at Visit 1- ScreeningBaseline Day 0 and will extend through Visit 4 Week 24-26. 